Research map: GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital

Back to the article

Papers in this map

  1. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls · Christoph Ulrich Correll · 2017 · 1756 citations · Cited by this paper
  2. HIV diagnosis following psychiatric hospitalization among a large cohort of privately-insured people in the United States, 2003–2024 · 2026 · Related
  3. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis · Carsten Rygaard Hjorthøj · 2017 · 1342 citations · Cited by this paper
  4. High Remission of Somatic Symptom Disorder in Irritable Bowel Syndrome Supports ICD-11 Exclusion of Comorbid BDD · 2026 · Related
  5. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis · Toby Pillinger · 2019 · 1082 citations · Cited by this paper
  6. An app-enhanced inpatient-to-post-discharge intervention model for suicidal patients: Acceptability, feasibility, and preliminary effectiveness · 2026 · Related
  7. Cardiovascular disease in patients with severe mental illness · René Ernst Nielsen · 2020 · 402 citations · Cited by this paper
  8. Overlapping but distinct: delirium and catatonia-related features in critically ill patients · 2026 · Related
  9. Severe Mental Illness and Cardiovascular Disease · Michael J. Goldfarb · 2022 · 235 citations · Cited by this paper
  10. Parenteral clomipramine in inpatient depression: a retrospective cohort study of treatment patterns and patient characteristics · 2026 · Related
  11. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022 · Jonathan Hirohiko Watanabe · 2023 · 209 citations · Cited by this paper
  12. Response to “Assessment of the family system in patients with medically unexplained symptoms” · 2026 · Related
  13. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials · Hon Jen Wong · 2025 · 192 citations · Cited by this paper
  14. A mixed-methods longitudinal study of demoralization and depression in breast cancer survivors · 2026 · Related
  15. Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study · Oliver Ian Brown · 2023 · 102 citations · Cited by this paper
  16. Mood disorders and incident ICU delirium: Distinct risk profiles across clinical subgroups and diagnostic subtypes · 2026 · Related
  17. Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis · Yee Hui Yeo · 2024 · 88 citations · Cited by this paper
  18. Urgent psychiatric referrals in the general hospital: Unscheduled consultations in a biopsychosocial perspective · 2026 · Related
  19. Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder · Rebecca C. Rossom · 2022 · 85 citations · Cited by this paper
  20. Beyond the binary: Clinical caution, capacity, and the cardiac catheterization laboratory in patients with serious mental illness · 2026 · Related
  21. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity · Ashok Ainkaran Ganeshalingam · 2025 · 55 citations · Cited by this paper
  22. Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia · Dan J. Siskind · 2025 · 53 citations · Cited by this paper
  23. Schizophrenia and type 2 diabetes risk: a systematic review and meta-analysis · Kai Dong · 2024 · 26 citations · Cited by this paper
  24. Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States · John W. Ostrominski · 2025 · 22 citations · Cited by this paper
  25. Semaglutide in Psychiatry—Opportunities and Challenges · Sri Mahavir Agarwal · 2024 · 15 citations · Cited by this paper
  26. Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials · D Gomes · 2024 · 12 citations · Cited by this paper
  27. Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis · Marco Spagnolo · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)